Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813230 | 0.85 | TTR (0.50) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL2191755 | 0.84 | ALDH1A1 (0.56) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL737305 | 0.84 | TTR (1.00) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL4350880 | 0.83 | TTR (0.48) | TTRTSHRCA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9064511 | 0.82 | ALDH1A1 (0.54) | TTRTSHRCA12CA1CA2 | |
| Bromide SCHEMBL28853691 | 0.82 | TTR (0.95) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL1759305 | 0.81 | TTR (0.56) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL4269298 | 0.78 | CA12 (0.70) | TTRCA12CA1CA2CA7 | |
| SCHEMBL30689081 | 0.78 | TTR (0.78) | TTRTSHRCA12CA1CA2 | |
| SCHEMBL1458206 | 0.78 | TTR (0.78) | TTRTSHRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116115764-A | Tetrahydroimidazo [4,5-C ] pyridine derivatives as PD-L1 internalization inducers | 因赛特公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-101688227-B | Macrolactams prepared by engineered biosynthesis | KOSAN BIOSCIENCES INC | 2013-07-24 | — | — | CN | disclosed |
| US-7855192-B2 | Macrolactams by engineered biosynthesis | KOSAN BIOSCIENCES, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855192-B2 | Macrolactams by engineered biosynthesis | KOSAN BIOSCIENCES, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855192-B2 | Macrolactams by engineered biosynthesis | KOSAN BIOSCIENCES, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| CN-101688227-A | Macrocyclic lactams by through engineering approaches biosynthesizing preparation | KOSAN BIOSCIENCES INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2121957-A1 | MACROLACTAMS BY ENGINEERED BIOSYNTHESIS | Kosan Biosciences, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008094438-A1 | MACROLACTAMS BY ENGINEERED BIOSYNTHESIS | KOSAN BIOSCIENCES INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094438-A1 | MACROLACTAMS BY ENGINEERED BIOSYNTHESIS | KOSAN BIOSCIENCES INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | KOSAN BIOSCIENCES INCORPORATED | 2008-08-07 | — | — | US | disclosed |
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | KOSAN BIOSCIENCES INCORPORATED | 2008-08-07 | — | — | US | disclosed |
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | KOSAN BIOSCIENCES INCORPORATED | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188450-A1 | A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer | HSP90AB2P, HSP90AB1, HSPA1B | TTR 3969/4885TSHR 4191/4885CA12 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.